Drug abuse has gradually become an increasing issue due to the use of non-medical prescription drugs. Thus, pharmacovigilance and drug safety has become an even more crucial aspect for ensuring patient safety by monitoring adverse drug reactions and evaluating the safe use of medicines. To do this, robust procedures must be established while keeping in […]
Nanobodies are engineered small proteins that recognize and specifically bind to an antigen to initiate an appropriate signal- like antibodies. However, nanobodies bind to antigens with greater specificity and display other advantages over conventional antibodies. Extracted from camelids, these antibodies were found to comprise only of heavy chains, while demonstrating the same functions as conventional
Nanobodies vs Antibodies in the Fight Against Covid Read More »
From pre-clinical phases to post-marketing follow-up studies, the drug development process is a challenging, expensive, and time-consuming process that can take many years to complete. Companies spend millions of dollars and countless hours to test the effectiveness of their new drugs. To save cost and time, pharmaceutical companies are incorporating ai in drug discovery process
Enhancing Drug Discovery Process Through Artificial Intelligence Read More »
CPhI provides a networking platform for pharmaceutical industry leaders. As America accounts for approximately 40% of global pharmaceutical sales, CPhI North America is the ideal event that encourages pharmaceutical experts to interact with each other regarding innovation within the industry. The 3-day, in-person, conference will touch on a broad horizon of relevant topics including market
Drug safety is all about the right patient receiving the right drug at the right time for an improved outcome for each patient. To achieve this, a Qualified Person Responsible for Pharmacovigilance (QPPV) Training is held responsible for the pharmacovigilance services management of the quality of a pharmaceutical company. This could be a person who
Why QPPV Training is the Key to Pharmacovigilance Success? Read More »
The Russia-Ukraine war has undoubtedly affected millions of people in and around the world. Several industries have taken a huge hit where operational and business continuity has been threatened, the pharmaceutical industry being one of them. From the delays along the drug development pipeline, to non-compliance products in the market being at risk, the industry
The impact of the Russia-Ukraine war on clinical trials Read More »
The 7th of April 2022 marked the 74th anniversary of the founding of WHO in 1948 which is celebrated annually as ‘World Health Day’. Each year draws attention to a specific health topic of concern to people all over the world. The onset of the pandemic has created history and has affected billions of people
The First WHO Global Centre For Traditional Medicine in Gujurat, India Read More »
DDreg RegTech focuses on technologies that may facilitate the delivery of regulatory requirements more efficiently and effectively than existing capabilities. The global adoption of RegTech is a result of increased regulatory scrutiny, compliance costs, development of artificial intelligence, evolution of data science and increasing demands regarding cost-effective compliance solutions. With ever changing regulatory requirements, pharmaceutical
DDReg’s RegTech space: your regulatory solution for achieving rapid market access Read More »
The healthcare ecosystem is driven by several factors. Government vision, successful partnerships, modern legislation, and adoption of innovation are some of the most crucial ones from a regulation point of view. Regulatory affairs (RA) bridge the gap between regulatory authorities and market access for drugs allowing patient empowerment by increasing drug availability. With ever-changing laws,
DDReg Pharma: Silver Sponsors of the 7th GCC Pharma Summit 2022, Dubai, UAE Read More »
Biologics development in Biologic medicinal products, particularly biosimilars, has revolutionized the treatment of chronic conditions. As biologic products lose patent protection, biosimilars emerge as more readily accessible treatment alternatives. In the European Union (EU), the European Medicines Agency (EMA) is responsible for product approval. The EMA was the first regulatory authority to establish a regulatory
Biologics development & regulatory approval – EMA perspective Read More »
